{
  "id": 14277852,
  "title": "GLP-1 treatment linked to lower risk of hospitalization and death in older adults with fatty liver disease",
  "url": "https://urgent.news/2026/10/13/glp-1-treatment-linked-to-lower-risk-of-hospitalization-and-death-in",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-10-13T19:40:17.000Z",
  "source": {
    "name": "Medical Xpress",
    "slug": "medical-xpress",
    "url": "https://medicalxpress.com/news/2026-10-glp-treatment-linked-hospitalization-death.html"
  },
  "original_language": "en",
  "account": "A new study from the Houston Methodist Research Institute suggests that older adults with a specific type of fatty liver disease who took GLP-1-based medications had significantly lower risks of complications, hospitalization, and death compared to those who did not receive the treatment. Dr. Eleftherios Mylonakis, the study's lead researcher, stated that GLP-1 therapy reduced the risk of a serious liver complication by 28% and the risk of death from any cause by 45%. Patients also experienced fewer hospitalizations during the follow-up period.\n\nThe research, published in the journal Age and Ageing, analyzed health records from 69 U.S. healthcare organizations and compared 43,930 older adults (average age of 71.8 years) who began GLP-1 treatment to 43,930 similar patients who did not receive the medication. The study found that while GLP-1 therapy offered benefits, it also led to an increase in diagnoses of osteoporosis and retinopathy. However, there was no reduction in the risk of heart attack or stroke.\n\nThe researchers noted that randomized trials are necessary to confirm these findings and to determine which patients would benefit most from GLP-1 therapy and who may require closer monitoring. Despite growing interest in GLP-1 treatments, evidence about their long-term effects in older adults remains limited. The study's authors emphasized that these associations do not prove a cause-and-effect relationship.",
  "summary": "A new Houston Methodist Research Institute study finds that older adults with metabolic dysfunction-associated steatotic liver disease (MASLD) who received GLP-1-based treatment experienced significantly lower risks of liver disease–related complications, hospitalization and death compared with similar patients who did not receive the treatment.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}